Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?

Anna Gidari Samuele Sabbatini Sabrina Bastianelli Sara PierucciChiara BustiElisabetta SvizzerettoAndrea TommasiCarlo PallottoElisabetta SchiaroliDaniela Francisci

Published in: Viruses (2024)

Tixagevimab/cilgavimab efficacy wanes against novel subvariants. This underscores the critical need for ongoing adaptation and vigilance in prophylactic strategies to effectively counter the dynamic and unpredictable nature of the COVID-19 pandemic.

Keyphrases

coronavirus disease
sars cov
copy number
stress induced
respiratory syndrome coronavirus